Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy


Investors are bullish on biotech research focused on cancer, despite the uncertainty that the science will translate to marketable products. So far, 38 biotechnology companies have gone public in 2018, raising nearly $4 billion, according to figures released by Bloomberg last week.



from Biotech News